Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic tranexamic acid for bleeding reduction after burn wound debridement
IRCT20240227061117N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tranexamic acid in burn injury (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Hemoglobin change, Hematocrit change and 3 more. Started Mar 2024; status: completed.
02
Drugs
tranexamic acid
03
Conditions
burn injury
Beyond the preview
Go deeper on IRCT20240227061117N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240227061117N1.